0001209191-15-009188.txt : 20150203
0001209191-15-009188.hdr.sgml : 20150203
20150203204711
ACCESSION NUMBER: 0001209191-15-009188
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150130
FILED AS OF DATE: 20150203
DATE AS OF CHANGE: 20150203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MYLAN INC.
CENTRAL INDEX KEY: 0000069499
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 251211621
STATE OF INCORPORATION: PA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1000 MYLAN BOULEVARD
CITY: CANONSBURG
STATE: PA
ZIP: 15317
BUSINESS PHONE: 724-514-1800
MAIL ADDRESS:
STREET 1: 1000 MYLAN BOULEVARD
CITY: CANONSBURG
STATE: PA
ZIP: 15317
FORMER COMPANY:
FORMER CONFORMED NAME: MYLAN LABORATORIES INC
DATE OF NAME CHANGE: 19920703
FORMER COMPANY:
FORMER CONFORMED NAME: FRM CORP
DATE OF NAME CHANGE: 19711003
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PARRISH MARK W
CENTRAL INDEX KEY: 0001236452
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-09114
FILM NUMBER: 15573250
MAIL ADDRESS:
STREET 1: C/O CARDINAL HEALTH INC
STREET 2: 7000 CARDINAL PLACE
CITY: DUBLIN
STATE: OH
ZIP: 43235
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-01-30
0
0000069499
MYLAN INC.
MYL
0001236452
PARRISH MARK W
1000 MYLAN BLVD
CANONSBURG
PA
15317
1
0
0
0
Common Stock
2015-01-30
4
M
0
12147
14.27
A
41807
D
Common Stock
2015-01-30
4
M
0
2709
20.52
A
44516
D
Common Stock
2015-01-30
4
S
0
14856
53.7283
D
29660
D
Common Stock
2015-02-02
4
M
0
8917
20.52
A
38577
D
Common Stock
2015-02-02
4
M
0
10864
23.90
A
49441
D
Common Stock
2015-02-02
4
M
0
3438
21.00
A
52879
D
Common Stock
2015-02-02
4
S
0
23219
52.8739
D
29660
D
Common Stock
2015-02-03
4
M
0
9720
21.00
A
39380
D
Common Stock
2015-02-03
4
M
0
6623
31.63
A
46003
D
Common Stock
2015-02-03
4
S
0
16343
53.0135
D
29660
D
Non-Employee Director Stock Option - Right to Buy
14.27
2015-01-30
4
M
0
12147
0.00
D
2019-09-01
Common Stock
12147
0
D
Non-Employee Director Stock Option - Right to Buy
20.52
2015-01-30
4
M
0
2709
0.00
D
2020-05-14
Common Stock
2709
8917
D
Non-Employee Director Stock Option - Right to Buy
20.52
2015-02-02
4
M
0
8917
0.00
D
2020-05-14
Common Stock
8917
0
D
Non-Employee Director Stock Option - Right to Buy
23.90
2015-02-02
4
M
0
10864
0.00
D
2021-05-06
Common Stock
10864
0
D
Non-Employee Director Stock Option - Right to Buy
21.00
2015-02-02
4
M
0
3438
0.00
D
2022-05-04
Common Stock
3438
9720
D
Non-Employee Director Stock Option - Right to Buy
21.00
2015-02-03
4
M
0
9720
0.00
D
2022-05-04
Common Stock
9720
0
D
Non-Employee Director Stock Option - Right to Buy
31.63
2015-02-03
4
M
0
6623
0.00
D
2023-05-28
Common Stock
6623
0
D
Represents acquisition of Mylan common stock upon exercise of stock options granted on September 1, 2009.
Represents acquisition of Mylan common stock upon exercise of stock options granted on May 14, 2010.
Represents the weighted average price of shares sold by the broker on behalf of certain non-employee directors and executive officers of Mylan on January 30, 2015. The broker sold, in the aggregate on behalf of such non-employee directors and executive officers, 403,595 shares in transactions ranging from $53.01 to $54.00 with a weighted average price of $53.5684 as well as 205,341 shares in transactions ranging from $54.005 to $54.25 with a weighted average price of $54.0425. The proceeds of all such sales were allocated to the applicable non-employee directors and executive officers on a pro rata basis based on the number of shares sold by such person.
Represents acquisition of Mylan common stock upon exercise of stock options granted on May 6, 2011.
Represents acquisition of Mylan common stock upon exercise of stock options granted on May 4, 2012.
Represents the weighted average price of shares sold by the broker on behalf of certain non-employee directors and executive officers of Mylan on February 2, 2015. The broker sold, in the aggregate on behalf of such non-employee directors and executive officers, 937,763 shares in transactions ranging from $52.23 to $53.22 with a weighted average price of $52.8646 as well as 13,957 shares in transactions ranging from $53.23 to $53.745 with a weighted average price of $53.5027. The proceeds of all such sales were allocated to the applicable non-employee directors and executive officers on a pro rata basis based on the number of shares sold by such person.
Represents acquisition of Mylan common stock upon exercise of stock options granted on May 28, 2013.
Represents the weighted average price of shares sold by the broker on behalf of certain non-employee directors and executive officers of Mylan on February 3, 2015. The broker sold, in the aggregate on behalf of such non-employee directors and executive officers, 520,475 shares in transactions ranging from $52.50 to $53.25 with a weighted average price of $52.8739 as well as 149,400 shares at $53.50 and 1 share at $54.50. The proceeds of all such sales were allocated to the applicable non-employee directors and executive officers on a pro rata basis based on the number of shares sold by such person.
This option exercise and the related sale of the underlying common stock were executed pursuant to a 10b5-1 trading plan dated November 9, 2014.
These options vested in full on September 1, 2010.
These options vested in full on May 14, 2011.
These options vested in full on May 6, 2012.
These options vested in full on May 4, 2013.
These options vested in full on May 28, 2014.
As disclosed in the proxy statement filed by Mylan Inc. ("Mylan") on December 24, 2014 and the Form 8-K filed by Mylan on November 5, 2014, the filing person has exercised the stock options shown on this Form 4 to mitigate the effects of the excise tax under Section 4985 of the Internal Revenue Code of 1986, as amended, in connection with the proposed acquisition (the "Transaction") by a new public company organized in the Netherlands of both Mylan and Abbott Laboratories' non-U.S. developed markets specialty and branded generics business and has sold the shares reported on this Form 4 to mitigate the tax and other costs imposed as a result of such exercises and the Transaction.
/s/ Bradley L. Wideman, by power of attorney
2015-02-03